RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors Academic Article uri icon

Overview

MeSH Major

  • Carcinoma, Squamous Cell
  • Genes, ras
  • Indoles
  • Mutation
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins B-raf
  • Skin Neoplasms
  • Sulfonamides

abstract

  • Mutations in RAS, particularly HRAS, are frequent in cutaneous squamous-cell carcinomas and keratoacanthomas that develop in patients treated with vemurafenib. The molecular mechanism is consistent with the paradoxical activation of MAPK signaling and leads to accelerated growth of these lesions. (Funded by Hoffmann-La Roche and others; ClinicalTrials.gov numbers, NCT00405587, NCT00949702, NCT01001299, and NCT01006980.).

authors

publication date

  • January 19, 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3724537

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1105358

PubMed ID

  • 22256804

Additional Document Info

start page

  • 207

end page

  • 15

volume

  • 366

number

  • 3